Your Health, We Care
Indications: Ixazomib, in combination with lenalidomide and dexamethasone, is indicated for the treatment of patients with multiple myeloma who have received at least one prior line of therapy.
Usage Restrictions: Ixazomib is not recommended for use during the maintenance treatment phase, nor is it recommended to use ixazomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma outside of controlled clinical trials.
from FDA,2024.07
Ixazomib is indicated for the treatment of multiple myeloma, a type of bone marr···【more】
Release date：2026-01-07Recommended：23
Ixazomib is a second-generation proteasome inhibitor that has emerged as a pivot···【more】
Release date：2026-01-07Recommended：24
Ixazomab is suitable for the treatment of multiple myeloma.【more】
Release date：2026-01-06Recommended：17
